CLEVELAND, Oct. 31, 2007 (PRIME NEWSWIRE) -- Athersys, Inc. (OTCBB:AHYS) today announced it will present at the Lazard Capital Markets Fourth Annual Healthcare Conference to be held November 27-28, 2007, at The New York Palace in New York City.
Gil Van Bokkelen, Chairman and Chief Executive Officer, and William (B.J.) Lehmann, President and Chief Operating Officer, will present on Tuesday, November 27, 2007 at 3:30 p.m. Eastern Time. The presentation will be available as a live audio webcast plus slides and then archived for 90 days after the conference at: http://www.wsw.com/webcast/lz4/ahys.ob/.
About Athersys, Inc.
Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is also developing MultiStem(r), a patented, adult-derived "off the shelf" stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications.